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Introduction. Obesity and prostate cancer are among the more common health issues aﬀecting men in the United States. Methods.
We retrospectively reviewed morbidly obese (BMI ≥ 40kg/m
2) patients undergoing RALP between 2004–2009 at our institution.
Parameters including operative time, estimated blood loss, hospital stay, pathology, and complication rate were examined. Results.
A total of 15 patients were included, with a mean BMI of 43kg/m2. Mean preoperative PSA was 5.78ng/dL, and Gleason score
was 6.6. Mean operative time was 163 minutes, and mean estimated blood loss was 210mL. The mean hospital stay was 1.3 days.
Positive margins were noted in 2 (13%) patients, each with pT3 disease. There were no blood transfusions, open conversions, or
Clavien Grade II or higher complications. Conclusions. In our experience, RALP is feasible in morbidly obese patients. We noted
several challenges in this patient population which were overcome with modiﬁcation of technique and experience.
1.Introduction
The prevalence of obesity in the United States has increased
over the past few decades. Recently, the National Health and
Nutrition Examination Survey (NHANES) reported an age-
adjusted prevalence of obesity in 2007 and 2008 to be 33.8%
in men and 35.5% in women [1]. While in past years the
prevalence of obesity has increased dramatically, it appears
that the rate of increase may be slowing. The World Health
Organization (WHO) deﬁnition of obesity is based on body
mass index (BMI), and includes Grade I (BMI between
30 and 34.9kg/m2), Grade II (BMI between 35kg/m2 and
39.9kg/m2), and Grade III (BMI of 40kg/m2 and higher).
Obesity contributes to a number of health conditions,
including diabetesmellitus,hypertension,osteoarthritis, and
some malignancies [2]. In regards to prostate cancer, some
data suggests that obese patients may have less favorable
disease pathology [3–5].
Obesity can make any surgical procedure more challeng-
ing and increase the risks of morbidity. The introduction
of robot-assisted laparoscopic radical prostatectomy (RALP)
can help overcome some of these technical diﬃculties,
but also introduces other procedural challenges. Several
institutionshavereportedexperienceintheobesepopulation
with open radical retropubic prostatectomy (RRP), radical
perineal prostatectomy (RPP), and minimally invasive rad-
ical prostatectomy (MIRP), including laparoscopic radical
prostatectomy(LRP),andRALP[6–23].Manyofthepatients
included in these studies meet the criteria for Class I or Class
II obesity, with a lower incidence of Class III obesity.
At our institution, patients with prostate cancer are not
excluded from surgical management on the basis of obesity
alone. We have subjectively found that RALP in the obese,
and especially the morbidly obese patient, can be technically
challenging. We sought to describe the objective outcomes
of RALP in the morbidly obese patient, and to review the
literature for outcomes of obese patients undergoing radical
prostatectomy.
2. Methods
After obtaining institutional review board (IRB) approval,
the records of patients undergoing RALP between 2004 and
2009by2surgeons(RM,IS)atourinstitutionwerereviewed.2 Prostate Cancer
Morbidly obese patients, that is, Class III obesity (BMI ≥
40kg/m2), were identiﬁed and included in the review. The
medical records were reviewed for relevant demographic
factors, clinical staging characteristics, operative time, esti-
mated blood loss (EBL), length of hospital stay (LOS), blood
transfusion rate, incidence and type of complication, and
pathological characteristics.
3. Results
A total of 15 patients with a mean BMI of 43kg/m2 (range
40–53) and mean weight of 128.2kg (range 93–173) were
identiﬁed.Medicalcomorbiditiesincludedhyperlipidemiain
87%, diabetes mellitus in 27%, hypertension in 73%, and
coronary artery disease in 20%. Mean preoperative prostate
speciﬁc antigen (PSA) was 5.78ng/dL and mean biopsy
Gleason score was 6.6 (range 6–8). Mean operative time was
163 minutes (range 115–250) and mean estimated blood
loss was 210mL (range 50–400). Patients remained in the
hospital on average 1.3 days (range 1-2) after surgery. Final
pathology revealed pT2a (N = 3), pT2c (N = 8), pT3a (N =
3), and pT3b (N = 1). The pathologic Gleason score was 5
(N = 1),6 (N = 6),7 (N = 7), and 9 (N = 1).Mean prostate
volume was 48.5 grams (range 37–62). Positive margins were
noted in 2 (13%) of the patients, each of whom had pT3
disease. There were no blood transfusions, conversion to an
open procedure, case abortions, or Clavien grade II or higher
complications.
In comparison, 365 nonobese patients undergoing RALP
during the same time period had a mean BMI of 27.8. In this
group, mean operative time was 180.7 minutes (range 90–
540) and mean estimated blood loss was 134mL (range 25–
500). The positive margin rate was 17.5%. Mean length of
stay was 1.1 days.
4. Discussion
The challenges of treating obese patients are not limited to
the urologic ﬁeld, and experience across all medical ﬁelds
expands as the incidence of obesity rises. From an anesthesia
standpoint, obese patients have a higher rate of medical
comorbidities [16]. These patients can be more challenging
for the anesthetist to manage during laparoscopic surgery,
as they may demonstrate arterial oxygenation insuﬃciency
and higher peak inspiratory pressures compared to non-
obesepatients[24].Obesepatientsmayalsobemorediﬃcult
to intubate due to altered neck or airway anatomy and
may have increased risk of pulmonary aspiration due to
higher gastric residual volumes. Vascular access can also
be more challenging due to excess soft tissue [25]. In the
early postoperative period, obese patients are at risk for
pulmonary complications due to the higher incidence of
obstructive sleep apnea (OSA) and the obesity hypoventi-
lation syndrome. When combined with general anesthesia
and narcotics, even mild cases of OSA can be dangerous.
These patients should be closely monitored postoperatively
to prevent serious pulmonary complications [25].
The challenges associated with obese surgical patients
are documented in the general surgery literature. Dindo
[26] reported outcomes of obese patients undergoing
elective general surgery procedures, ﬁnding these patients
demonstrated an increased need for blood transfusions and
a slightly higher risk of wound infection. The bariatric
surgery literature suggests that high-volume surgeons and
medical centers, those most accustomed to treating the obese
patient, have superior bariatric surgery outcomes [27, 28].
Both length of stay and mortality were decreased at one
institution that reports high volumes of bariatric surgery
[27].
Obesity as a factor in the surgical treatment of prostate
cancer has several implications. First, the cost of treating
the obese patient may be greater than treating a non-obese
patient. Bolenz [29] compared the costs associated with
RALP, RRP, and LRP in both obese and non-obese patients.
The authors found that all individual cost domains were
higher in the obese except for the room and bed cost.
They suggest this is mostly due to the higher operating
room service and anesthesia costs associated with longer
operating times. When broken down by surgical technique,
both LRP and RRP were associated with higher costs in the
obese patient, but RALP showed no diﬀerence in cost when
comparing obese and non-obese patients.
Oncologic outcomes in obese patients may be less
favorable when compared to non-obese patients. Freedland
[30] found a statistically signiﬁcant association between
patient obesity and positive surgical margins (PSMs) early
in the cohort’s experience with RRP. Later in the experience,
there was a trend toward higher grade disease in obese
patients. They conclude that while the association between
obesity and PSM has decreased over time, the association
between obesity and higher grade cancer and advanced
stage has become stronger. In another review of patients
undergoing RRP, Siddiqui et al. [3] found that obese patients
had slightly higher rates of Gleason score 8–10 on both
biopsy and pathology specimens. In addition, PSM’s were
more common in the obese patients. Body mass index
did not aﬀect biochemical recurrence-free survival, cancer-
speciﬁc survival, or overall survival. In a series of patients
undergoing RALP, Boorjian et al. [8] found that PSMs were
more likely to be found posteriorly in the obese patients and
at the apex in non-obese patients. Overweight and obese
patients were also more likely to have pathologic stage T3
and T4 disease, higher grade disease, and higher volume
tumors. While still controversial, it is possible that obesity
can impact tumor biology, predisposing obese patients to
more aggressive variants of prostate cancer.
The surgical outcomes of radical prostatectomy in the
obese patient vary by the type of surgery and by series.
Radical perineal prostatectomy (RPP) is believed by some
to be advantageous in the obese, as the anterior abdominal
panniculus and dorsal venous complex are avoided. Yang et
al. [19] compared obese and non-obese patients undergoing
RPP. Similar estimated blood loss, length of stay, operative
times, and PSM’s were noted, but obesity was associated
with the risk of complications, especially lower extremity
neuropraxia. In a group of morbidly obese patients
(average BMI 39.3) undergoing RPP, Boczko reported no
complications and no transfusions in seven patients [22].Prostate Cancer 3
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was described by Lindner [13]. While the incidence of
perioperative complications and blood transfusions was
similar, the authors found that EBL was higher in the
obese group and operative times in the obese were longer.
Obese patients experienced a similar length of hospital stay,
PSM rate, and pathologic Gleason score and stage. Another
series reported a higher rate of wound infection, urinary
incontinence, and bladder neck contracture in obese patients
undergoing RRP [21].
Minimally-invasive radical prostatectomy (MIRP) can
also be oﬀered to the obese patient, though the surgeon must
consider the challenges unique to laparoscopic surgery. Both
LRP and RALP require steep Trendelenburg positioning,
and the attendant risks associated with transperitoneal or
extraperitoneal laparoscopy. We review the outcomes of LRP
and RALP in the obese patient.
The surgical outcomes associated with LRP in the obese
population are described in a number of series. In a review
of conversions from LRP to open RRP, Bhayani found that
obesity was a risk factor for conversion [7]. The authors
suggest that obese patients should not be included early in
a surgeon’s LRP experience. Several authors have found that
LRP operative time is increased in the obese population.
Brown noted that operative time was increased by a mean
of 29 minutes in patients with Class II and III obesity
[7]. In this series, length of stay, complication rates, and
pathological ﬁndings were similar in the obese and non-
obese groups. Another series found similar results, with
obesity adding an average of 38 minutes to the operative
time [31]. Another group reported longer operative time by
an average of 15 minutes, but similar estimated blood loss,
length of stay, and foley catheter duration. [23] Interestingly,
in this series, the PSM rate in obese patients with cT1c
disease was twice that of similar non-obese patients, though
this did not reach statistical signiﬁcance. Erectile function
was lower in the obese group, but again was not statistically
signiﬁcant. Similar ﬁndings were reported in a group of
patients undergoing extraperitoneal LRP. Operative time in
the obese patients averaged 20 minutes longer than the
non-obese patients. The complication rates, foley catheter
duration, urinary and erectile function at 6 month fol-
lowup, and PSM were similar between obese and non-obese
patients.
Robot-assisted laparoscopic prostatectomy has been
described in obese patients, with outcomes similar to those
of LRP. Mikhail et al. [14] noted similar conversion rates,
complication rates, pathological stage, PSM rates, and sexual
and urinary function in obese and non-obese patients.
However,theﬁrstthreeconversionstoopensurgeryoccurred
in obese patients due to bleeding, slow progression, or
to optimize oncologic outcomes. The authors suggest that
RALP can be safely performed in the obese patient once the
surgeon is experienced with the technique. The authors also
found that operative time and EBL was signiﬁcantly greater
in obese patients compared to non-obese patients. In an
update from the same institution, Wiltz et al. [16]r e p o r t s
that EBL was similar between obese and non-obese patients,
perhaps an improvement reﬂecting more experience. Several
other interesting ﬁndings were noted. First, there was a
higher open conversion rate among obese patients. Five of
the six conversions in obese patients occurred during the
initial 100 cases, and were due to failure of the surgery
to progress appropriately. Overall, the case abortion rate
was similar between obese and non-obese patients, but the
incidence of aborted procedures due to respiratory distress
was signiﬁcantly higher in the obese patients. Obese patients
also had lower preoperative Sexual Health Inventory for
Men (SHIM) scores at baseline and less favorable return of
continence and potency at 12 and 24 months compared to
non-obese patients. The ﬁndings of this study suggest that
a large series of patients with followup for greater than one
year is ideal to detect diﬀerences between the obese and non-
obese patient groups.
Ahlering also found that postoperative continence rates
are worse in obese patients [6]. These patients also exhibited
signiﬁcantly lower baseline (preoperative) SHIM scores,
peak urinary ﬂow rates, urinary bother scores, and voided
urinary volumes. The authors also found that obese patients
experienced an increase in perioperative complications, and
thatthesecomplicationsweremoreseverethanthoseinnon-
obese patients.
Several other series report RALP outcomes in obese
patients. Similar to other authors, Herman et al. [18]
reported increased operative time and EBL among obese
patients undergoing RALP. The obese patients also had a
higher rate of PSM’s, though there were no diﬀerences
in pathological stage, Gleason score, complication rates,
and the incidence of biochemical recurrence one year after
surgery. Castle also noted greater operative time and EBL
in the obese patients undergoing RALP [10]. In addition,
this group found higher PSM rates and higher pathological
tumor volumes in the obese patients. Boorjian also found
a trend toward higher rates of PSM in the obese patients
[8]. When evaluating the site of the PSM’s, obese patients
were more likely to have a posterior PSM, while non-
obese patients more often had a PSM at the apex. The
obese patients in this institution’s series had greater EBL
and operative time, but the length of stay, transfusion
rates, and complication rates were similar. Finally, Boczko
found that obese patients undergoing extraperitoneal RALP
experienced similar operative times, EBL, preoperative PSA,
clinical and pathological stages, specimen weights, PSM
rates,6monthcontinencerates,andcomplicationrateswhen
compared to non-obese patients [17].
Reported outcomes in patients undergoing MIRP vary
between series. It is likely that a number of factors inﬂuence
theseoutcomes.Forinstance,oneoftheinstitutionsreported
diﬀerent results with a larger cohort of patients and longer
followup. In addition, the degree of obesity varied between
institutions and series, which undoubtably inﬂuence out-
comes.
W er e p o r tas e r i e so fm o r b i d l yo b e s ep a t i e n t s( B M I
≥ 40), with favorable perioperative outcomes, speciﬁcally
no conversions to open surgery, case abortions, or early
perioperative complications. These outcomes may be partly
attributed to the robotic case volume at our institution,
which allows the entire surgical team, including the4 Prostate Cancer
operating room staﬀ, anesthetist, and surgeon, to feel more
comfortable with more challenging patients.
RALP in the morbidly obese patient can be challeng-
ing. Close communication with the anesthesiology team
is critical, as these patients may be more sensitive to
pneumoperitoneum and steep Trendelenburg. Cardiology
clearance in these patients, who are more likely to have
medical comorbidities [16], is well advised. When position-
ing the patient, the extremities must be carefully padded
to avoid neuropraxia. The patient’s weight should be taken
into consideration to avoid any additional pressure on the
arms when tucked at the patient’s side. The table armboards
may be added to provide additional room for adequate
padding of the upper extremities. Trocar placement should
be modiﬁed based on the patient’s body habitus. Longer
instruments and trocars may be necessary, and the trocars
may actually need to be placed in a more cephalad position
ontheabdomenasmeasuredfromthepubicsymphysis.This
is necessary due to a more vertical trajectory from the skin
toward the pelvis due to the protuberance of the abdomen
[14]. Finally, RALP in the obese patient, and especially in
the morbidly obese patient, is more likely to have favorable
outcomes when performed later in the surgeon’s learning
curve. Once the technique of RALP has been mastered, and
the surgeon can troubleshoot problems in the non-obese
patient, the challenges posed by the obese patient can be
more successfully overcome.
5. Conclusion
To our knowledge, this is the largest series reporting outco-
mes of morbidly obese patients undergoing RALP. We report
an acceptable PSM rate, no conversions to open surgery, no
case abortions, and few perioperative complications. Robot-
assisted laparoscopic prostatectomy, while technically chal-
lengingintheobesepatient,isanappropriatesurgicaloption
when oﬀered by experienced surgeons.
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